[go: up one dir, main page]

WO2002060533A3 - Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen - Google Patents

Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen Download PDF

Info

Publication number
WO2002060533A3
WO2002060533A3 PCT/EP2002/000704 EP0200704W WO02060533A3 WO 2002060533 A3 WO2002060533 A3 WO 2002060533A3 EP 0200704 W EP0200704 W EP 0200704W WO 02060533 A3 WO02060533 A3 WO 02060533A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
effects
compositions containing
few side
containing beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000704
Other languages
English (en)
French (fr)
Other versions
WO2002060533A2 (de
Inventor
Karl-Heinz Bozung
Michel Pairet
Richard Reichl
Alexander Walland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to CA002436510A priority Critical patent/CA2436510A1/en
Priority to AU2002252981A priority patent/AU2002252981A1/en
Priority to EP02722033A priority patent/EP1357976A2/de
Publication of WO2002060533A2 publication Critical patent/WO2002060533A2/de
Publication of WO2002060533A3 publication Critical patent/WO2002060533A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft neuartige Arzneimittelkompositionen auf der Basis von langwirksamen Beta2-Agonisten und Oxitropiumsalzen, Verfahren zu deren Herstellung sowie deren Verwendung bei der Therapie von Atemwegserkrankungen.
PCT/EP2002/000704 2001-02-01 2002-01-24 Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen Ceased WO2002060533A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002436510A CA2436510A1 (en) 2001-02-01 2002-01-24 Pharmaceutical compositions with few side effects
AU2002252981A AU2002252981A1 (en) 2001-02-01 2002-01-24 Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
EP02722033A EP1357976A2 (de) 2001-02-01 2002-01-24 Arzneimittelkompositionen mit geringeren nebenwirkungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10104370A DE10104370A1 (de) 2001-02-01 2001-02-01 Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10104370.8 2001-02-01

Publications (2)

Publication Number Publication Date
WO2002060533A2 WO2002060533A2 (de) 2002-08-08
WO2002060533A3 true WO2002060533A3 (de) 2002-12-12

Family

ID=7672383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000704 Ceased WO2002060533A2 (de) 2001-02-01 2002-01-24 Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen

Country Status (5)

Country Link
EP (1) EP1357976A2 (de)
AU (1) AU2002252981A1 (de)
CA (1) CA2436510A1 (de)
DE (1) DE10104370A1 (de)
WO (1) WO2002060533A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
JP2009504624A (ja) 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827178A1 (de) * 1998-06-18 2000-04-27 Boehringer Ingelheim Pharma Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen
US6238647B1 (en) * 1991-12-12 2001-05-29 Glaxo Group Limited Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238647B1 (en) * 1991-12-12 2001-05-29 Glaxo Group Limited Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
DE19827178A1 (de) * 1998-06-18 2000-04-27 Boehringer Ingelheim Pharma Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAZZOLA, M. ET AL.: "Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 12, 1999, pages 267 - 271, XP002210290 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US7462645B2 (en) 2003-07-10 2008-12-09 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7465756B2 (en) 2003-07-10 2008-12-16 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7473710B2 (en) 2003-07-10 2009-01-06 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7541385B2 (en) 2003-07-10 2009-06-02 Chaudry Imtiaz A Bronchodilating β-agonist compositions and methods
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Also Published As

Publication number Publication date
EP1357976A2 (de) 2003-11-05
AU2002252981A1 (en) 2002-08-12
CA2436510A1 (en) 2002-08-08
DE10104370A1 (de) 2002-08-08
WO2002060533A2 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EG24228A (en) Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
DE60202477D1 (de) Vorrichtung zur verabreichung einer substanz
WO2001076575A3 (en) The treatment of respiratory diseases
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2002085309A9 (en) Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2003000172A3 (en) Methods, pharmaceutical compositions, oral compositions, filters and tobacco products for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AU3598299A (en) Improved compositions for inhalation
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
BR0009080A (pt) Método de tratamento da apnéia do sono
HU0102987D0 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
WO2003030862A3 (en) Anaesthetic compositions and method for their administration
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2002074034A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002722033

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2436510

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002722033

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWR Wipo information: refused in national office

Ref document number: 2002722033

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002722033

Country of ref document: EP